Reena Patel
Ophthalmology · Wichita, KSNPI 1346288149
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,983 of the $6,661 with a category attached, or 74.8%. It is spread thinly across 23 manufacturers, the largest accounting for just 18.7%.
Across 123 payments — averaging $54.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$1K
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Rxsight Inc$735
- Biotissue Holdings Inc.$249
- Sight Sciences, Inc.$237
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$391%
- Travel & lodging$1,04116%
- Food & beverage$4,98375%
- Education$981%
- Gifts$691%
- Entertainment$1652%
- Other$2664%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 20 | $1,244 |
| Alcon | 45 | $1,241 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $1,161 |
| Rxsight Inc | 12 | $735 |
| Biotissue Holdings Inc. | 2 | $249 |
| Sight Sciences, Inc. | 9 | $237 |
| Apellis Pharmaceuticals, Inc. | 2 | $233 |
| Mallinckrodt Hospital Products Inc. | 2 | $222 |
| Bausch & Lomb Americas Inc. | 5 | $213 |
| AbbVie(2 entities) | 6 | $210 |
| Carl Zeiss Meditec USA, Inc. | 1 | $187 |
| Optos, Inc. | 1 | $165 |
| NEW World Medical,inc. | 1 | $150 |
| The Cameron-ehlen Group, Inc. | 1 | $145 |
| Fujifilm Healthcare Americas Corporation | 2 | $86 |
| Tarsus Pharmaceuticals, Inc. | 1 | $35 |
| Sun Pharmaceutical Industries Inc. | 2 | $32 |
| Dompe US, Inc. | 2 | $31 |
| Sanofi | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $15 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,041
- Tecnis Multifocal Family of 1-piece IOLS$1,041
- Tecnis Symfony IOL$1,041
- iDoseTR$444
- Tecnis IOL$435
- OCT OPHTHALMOSCOPE$329
- PANORAMIC OPHTHALMOSCOPE$329
- iDose$269
- Syfovre$233
- AcrySof IQ PanOptix UV IOL$227
- RXSIGHT CONTACT LENS$223
- RXSIGHT INJECTOR CARTRIDGE$223
- RXSIGHT INJECTOR HANDPIECE$223
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$223
- LUMERA 700$187
- ScoutPro Osmolarity System$180
- NFC-700$165
- Kahook Dual Blade$150
- Clearpath$150
- Ahmed Glaucoma Valve$150
How this compares
$6,661 in reported general payments places this provider in the 85th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 289 | $217,861 |
| MieboPerfluorohexyloctane/Pf | 241 | $179,547 |
| XiidraLifitegrast | 88 | $79,629 |
| TyrvayaVarenicline Tartrate | 32 | $24,649 |
| CequaCyclosporine | 30 | $23,967 |
| Cyclosporine | 78 | $19,306 |
| LumiganBimatoprost | 45 | $16,188 |
| ProlensaBromfenac Sodium | 46 | $15,927 |
| CombiganBrimonidine Tartrate/Timolol | 41 | $12,409 |
| Alphagan PBrimonidine Tartrate | 51 | $11,405 |
| VyzultaLatanoprostene Bunod | 24 | $8,749 |
| BesivanceBesifloxacin Hcl | 32 | $7,087 |
| Travoprost | 65 | $5,628 |
| Prednisolone Acetate | 200 | $5,481 |
| RhopressaNetarsudil Mesylate | 17 | $5,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $213 | $267,924353 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $210 | $257,863426 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $32 | $23,96730 claims |
| AlconSimbrinza | $1,241 | $3,04115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Wichita
- Michele RigginsWichita$16K
- Finny JohnWichita$12K
- Jennifer BurgoyneWichita$4K
- Bilal FarhatWichita$3K
- Terria WinnWichita$3K
- Martin de la PresaWichita$2K
- Daniel DurrieOverland Park$974K
- John DoaneLeawood$496K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.